Vaughan David Investments Inc. IL Cuts Position in Johnson & Johnson (JNJ)

Vaughan David Investments Inc. IL trimmed its position in Johnson & Johnson (NYSE:JNJ) by 39.1% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 175,603 shares of the company’s stock after selling 112,518 shares during the period. Vaughan David Investments Inc. IL’s holdings in Johnson & Johnson were worth $20,665,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. Banque Pictet & Cie SA grew its position in Johnson & Johnson by 5.8% during the 3rd quarter. Banque Pictet & Cie SA now owns 858,711 shares of the company’s stock worth $111,641,000 after purchasing an additional 47,160 shares during the period. Novare Capital Management LLC grew its position in shares of Johnson & Johnson by 42.7% during the 3rd quarter. Novare Capital Management LLC now owns 84,642 shares of the company’s stock valued at $11,004,000 after acquiring an additional 25,318 shares during the period. Spectrum Management Group Inc. grew its position in shares of Johnson & Johnson by 129.2% during the 3rd quarter. Spectrum Management Group Inc. now owns 30,882 shares of the company’s stock valued at $4,015,000 after acquiring an additional 17,407 shares during the period. Pictet & Cie Europe SA grew its position in shares of Johnson & Johnson by 0.6% during the 3rd quarter. Pictet & Cie Europe SA now owns 67,520 shares of the company’s stock valued at $8,778,000 after acquiring an additional 400 shares during the period. Finally, NewSquare Capital LLC grew its position in shares of Johnson & Johnson by 2,088.7% during the 3rd quarter. NewSquare Capital LLC now owns 34,385 shares of the company’s stock valued at $221,000 after acquiring an additional 32,814 shares during the period. 65.53% of the stock is currently owned by hedge funds and other institutional investors.

A number of equities research analysts have recently commented on the company. Vetr upgraded Johnson & Johnson from a “hold” rating to a “buy” rating and set a $150.89 target price on the stock in a research report on Thursday, January 11th. Citigroup raised their target price on Johnson & Johnson from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Monday, October 23rd. Royal Bank of Canada restated a “buy” rating on shares of Johnson & Johnson in a research report on Tuesday, January 9th. Stifel Nicolaus raised their target price on Johnson & Johnson from $142.00 to $145.00 and gave the company a “hold” rating in a research report on Wednesday, January 24th. Finally, JPMorgan Chase & Co. cut Johnson & Johnson from an “overweight” rating to a “neutral” rating in a research report on Tuesday, January 2nd. Four research analysts have rated the stock with a sell rating, eight have given a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Johnson & Johnson presently has a consensus rating of “Hold” and a consensus price target of $146.16.

Johnson & Johnson (NYSE:JNJ) opened at $133.15 on Friday. The firm has a market cap of $357,710.00, a PE ratio of 341.41, a P/E/G ratio of 2.20 and a beta of 0.74. Johnson & Johnson has a 12 month low of $118.05 and a 12 month high of $148.32. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Tuesday, January 23rd. The company reported $1.74 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.72 by $0.02. The firm had revenue of $20.20 billion for the quarter, compared to analyst estimates of $20.08 billion. Johnson & Johnson had a net margin of 1.70% and a return on equity of 27.80%. Johnson & Johnson’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same period last year, the company posted $1.58 EPS. equities analysts anticipate that Johnson & Johnson will post 8.11 earnings per share for the current fiscal year.

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 13th. Investors of record on Tuesday, February 27th will be paid a $0.84 dividend. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Monday, February 26th. Johnson & Johnson’s dividend payout ratio is presently 861.54%.

WARNING: “Vaughan David Investments Inc. IL Cuts Position in Johnson & Johnson (JNJ)” was first published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this news story on another site, it was stolen and reposted in violation of international trademark & copyright law. The original version of this news story can be read at https://www.dispatchtribunal.com/2018/02/18/vaughan-david-investments-inc-il-cuts-position-in-johnson-johnson-jnj.html.

About Johnson & Johnson

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply